Review
SCIO-469 Scios Inc
Affiliations
- PMID: 15573872
Item in Clipboard
Review
SCIO-469 Scios Inc
Curr Opin Investig Drugs.
2004 Nov.
Abstract
SCIO-469 is a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor under development by Scios Inc as a potential oral therapy for inflammatory disorders. By July 2004, SCIO-469 was in phase lib clinical trials for rheumatoid arthritis.
Similar articles
-
p38 MAP kinase inhibitors: many are made, but few are chosen.Curr Opin Drug Discov Devel. 2005 Jul;8(4):421-30. Curr Opin Drug Discov Devel. 2005. PMID: 16022178 Review.
-
Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.Curr Opin Investig Drugs. 2006 Nov;7(11):1020-5. Curr Opin Investig Drugs. 2006. PMID: 17117592
-
Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.J Med Chem. 2010 Mar 25;53(6):2345-53. doi: 10.1021/jm9012906. J Med Chem. 2010. PMID: 19950901 No abstract available.
-
Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis.Curr Opin Investig Drugs. 2003 May;4(5):566-71. Curr Opin Investig Drugs. 2003. PMID: 12833650 Review.
-
Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase.Bioorg Med Chem Lett. 2009 Mar 1;19(5):1461-4. doi: 10.1016/j.bmcl.2009.01.023. Epub 2009 Jan 14. Bioorg Med Chem Lett. 2009. PMID: 19195885
Cited by
-
Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.Curr Med Chem. 2015;22(24):2819-57. doi: 10.2174/0929867322666150619104007. Curr Med Chem. 2015. PMID: 26087764 Free PMC article. Review.
-
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.Blood. 2006 Dec 15;108(13):4170-7. doi: 10.1182/blood-2006-05-023093. Epub 2006 Aug 29. Blood. 2006. PMID: 16940419 Free PMC article. Clinical Trial.
-
Differential influence of p38 mitogen activated protein kinase (MAPK) inhibition on acute phase protein synthesis in human hepatoma cell lines.Ann Rheum Dis. 2006 Jul;65(7):929-35. doi: 10.1136/ard.2005.043232. Epub 2005 Nov 3. Ann Rheum Dis. 2006. PMID: 16269426 Free PMC article.
-
Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis.Inflammopharmacology. 2019 Dec;27(6):1217-1227. doi: 10.1007/s10787-019-00593-6. Epub 2019 Apr 29. Inflammopharmacology. 2019. PMID: 31037574
-
The Developmental Transcription Factor p63 Is Redeployed to Drive Allergic Skin Inflammation through Phosphorylation by p38α.J Immunol. 2022 Jun 15;208(12):2613-2621. doi: 10.4049/jimmunol.2101160. Epub 2022 May 27. J Immunol. 2022. PMID: 35623662 Free PMC article.